Introduction {#sec1}
============

Cancers have become a major cause of mortality for human health over the past decade \[[@B1]\]. Digestive system tumors, consisting mainly of gastric cancer, colorectal cancer, hepatocellular carcinoma, esophageal cancer, pancreatic cancer, and gallbladder cancer, have been counted as the main cause for all the cancer-related mortality worldwide \[[@B2]\]. Due to the lack of sensitive imaging methods and biomarkers, large number of cancer patients are mostly detected at advanced stage, and the 5-year survival rate still remains far from satisfactory \[[@B3]\]. Recently, researchers have been devoting themselves in identifying the novel tumor biomarkers associated with tumor screening, diagnosis, prognosis, and evaluation of therapeutic efficacy to improve their survival status \[[@B4],[@B5]\]. As the incidence of cancers is on the rise \[[@B6]\], it is clinically urgent and necessary to explore reliable biomarkers which can predict prognosis in malignant cancers, especially for digestive system cancers.

Previous studies have shown that long non-coding RNAs (lncRNAs) with a length greater than 200 nts play a crucial role in cancer development, which can act as tumor suppressor genes or oncogenes \[[@B7]\]. The aberrant expression of lncRNAs has been confirmed in different kinds of cancers by comparing expression of tumor and paired adjacent non-cancerous tissue \[[@B8]\], which suggests that lncRNAs may be involved in the cancer occurrence and development.

The lncRNA X-inactive specific transcript (XIST) is necessary for X-chromosome inactivation in female mammals \[[@B11]\], which can recruit polycomb repressive complex 2 (PRC2), thus mediating repression of the entire chromosome and also maintaining the silent state. Recently, increasing studies have shown that XIST can function as a tumor suppressor gene or oncogene in different types of cancers, including nasopharyngeal carcinoma \[[@B14]\], non-small-cell lung cancer \[[@B15]\], esophageal squamous cell carcinoma \[[@B16]\], colorectal cancer \[[@B17]\], breast cancer \[[@B18]\], gastric cancer \[[@B19]\], cervical squamous cell carcinoma \[[@B20]\], pancreatic cancer \[[@B21]\], prostate cancer \[[@B22]\], bladder cancer \[[@B23]\], and so on. However, these studies have been moderately limited because of relatively small sample sizes and some results are controversial. Therefore, the present systematic review and quantitative meta-analysis were performed to assess the prognostic and clinicopathological roles of XIST in different types of cancers and further to evaluate its predictive value in digestive system tumors.

Materials and methods {#sec2}
=====================

Search strategy and literature selection {#sec2-1}
----------------------------------------

Up to 3 January 2018, eligible articles which evaluated XIST as a biomarker for the prognosis or clinicopathological characteristics for cancer patients were searched in several international databases, including PubMed, Embase, Web of Science, and Cochrane. To increase search sensitivity, we used a strategy involving both Medical Subject Heading terms and free-text words. The searched terms were listed as follows: ('lncRNA-', 'XIST') and ('cancer' or 'carcinoma' or 'tumor' or 'neoplasm') and ('prognosis' or 'prognostic' or 'survival' or 'outcome' or 'metastasis') or ('characteristic' or 'clinical features'). With respect to the retrieved articles, we first excluded the ones not relevant to cancers. Then, titles, abstracts, and full texts of retrieved articles were carefully scanned to eliminate the ones without usable data.

Inclusion and exclusion criteria {#sec2-2}
--------------------------------

Inclusion criteria were as following: (i) articles evaluating the relationship between XIST expression level and overall survival or clinicopathological parameters of any type of cancer; (ii) articles for which we can obtain hazard ratio (HR) and 95% confidence interval (95% CI) directly or extract HR and 95% CI from survival curves indirectly; (iii) articles published in English; (iv) available full-text articles; (v) research on humans. Exclusion criteria were as following: (i) articles absence of overall survival; (ii) excluding earlier or smaller sample size ones for duplicate publications as well as duplicate data; (iii) reviews, letters, or laboratory studies lacking original data; (iv) articles published in languages other than English.

Data extraction and quality assessment {#sec2-3}
--------------------------------------

Two investigators (Xuefang Liu and Xinliang Ming) extracted all the essential information from enrolled articles independently. According to the inclusion and exclusion criteria, we deliberately extracted the following information: (i) general information including primary author, year, age, and gender of the patients enrolled, detection method, normative reference, and sample size; (ii) clinicopathological characteristics including lymph node metastasis, distant metastasis, differentiation, and tumor stage; (iii) the relationship between expression level of XIST and overall survival; (iv) survival curves. Quality assessment was performed according to the reporting recommendations for tumor marker prognostic studies (REMARK) guideline.

Statistical analysis {#sec2-4}
--------------------

The meta-analysis was conducted with Stata SE12 Software (STATA Corp, College Station, Texas, U.S.A.). Odds ratios (ORs) with corresponding 95% CIs were performed to analyze the association of XIST expression level with lymph node metastasis, distant metastasis, differentiation, and tumor stage. HRs with corresponding 95% CIs were utilized to estimate the relationship between the expression level of XIST and prognosis of cancer patients. In detail, HRs were extracted by using two methods: (i) we directly obtained HRs from the publication; (ii) we estimated the HRs and 95% CIs by choosing several survival rates at specified times from the Kaplan--Meier survival curves using Engauge Digitizer version 4.1. Heterogeneity across the enrolled studies was quantitated with the *I^2^* statistics. The random-effect model was performed if heterogeneity was present (*I^2^* ≥ 50% or *P*≤0.05). Otherwise, the fixed-effect model was more appropriate. We evaluated publication bias by constructing a funnel plot with Begg's test.

Trial sequential analysis {#sec2-5}
-------------------------

The standards for meta-analysis with high quality should be as religious as single randomized trial \[[@B24]\]. It usually requires multiple tests in meta-analysis, thus increasing random error. Systematic or random errors might lead to unreliable results in meta-analyses. Trial sequential analysis (TSA) can create a line of TSA boundary value by adjusting threshold for significant level with sparse data. A *priori* information size (APIS) is considered as the sample size needed for a reliable and conclusive result. There appeared four cases: (i) the cumulative Z-curve crosses the traditional Z-value but fails to cross the TSA boundary value, indicating that more trials are necessary to confirm the positive result; (ii) the cumulative Z-curve crosses both of them, meaning that trials show positive results in advance; (iii) the cumulative Z-curve crosses neither of them, which suggests that that more trials are necessary to confirm the negative result; (iv) the cumulative Z-curve crosses APIS value but cannot cross the traditional Z-value. It can be assumed that there was no significance between the experimental group and the control group. It was performed by setting the required power and risk for type I and type II errors. In our study, TSA was performed by setting an overall type-I error of 5%, a 15% relative risk reduction (RRR), and a statistical test power of 80%.

Results {#sec3}
=======

Studies included {#sec3-1}
----------------

The literature search and selection process are shown in [Figure 1](#F1){ref-type="fig"}. A total of 792 articles were retrieved from PubMed, Embase, Cochrane Library, Web of Science, and Medline, amongst which 132 studies were relevant to cancers. After a careful view of the title, abstract, key words, and the full texts, 114 articles did not include the usable data. Amongst the 18 articles left, two articles were not available. One article with survival curves made of XIST and 53BP1 was finally excluded. Subsequently, 15 articles were enrolled in the current meta-analysis, including 11 studies for prognosis and 12 for clinicopathological characteristics. The relevant information of the studies included for prognosis and clinicopathological characteristics were respectively shown in [Tables 1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}.

![Flow diagram of the search and selection process](bsr-38-bsr20180169-g1){#F1}

###### Characteristics of studies included for prognosis

  Author                        Year   Country   Type     Method   Reference     Case number (high/low)   Survival analysis   Analysis type   Follow-up months   HR availability   Quality score
  ----------------------------- ------ --------- -------- -------- ------------- ------------------------ ------------------- --------------- ------------------ ----------------- ---------------
  Ma et al. \[[@B40]\]          2017   China     GC       RT-PCR   GAPDH         98                       OS                  Kaplan--Meier   60                 Indirectly        7
  Du et al. \[[@B22]\]          2017   China     PCa      RT-PCR   GAPDH         62                       OS                  Kaplan--Meier   36                 Indirectly        6
  Xiao et al. \[[@B45]\]        2017   Ukraine   CRC      RT-PCR   GAPDH         70                       OS                  Multivariate    100                Indirectly        6
  Wu et al. \[[@B16]\]          2017   China     ESCC     RT-PCR   GAPDH         64/63                    OS                  Multivariate    100                Indirectly        8
  Chen et al. \[[@B17]\]        2017   China     CRC      RT-PCR   GAPDH         58/57                    OS                  Kaplan--Meier   150                Indirectly        8
  Wei et al. \[[@B21]\]         2017   China     PC       RT-PCR   GAPDH/RNU6B   32/32                    OS                  Multivariate    30                 Indirectly        6
  Du et al. \[[@B38]\]          2017   China     Glioma   RT-PCR   GAPDH         35/34                    OS                  Multivariate    36                 Indirectly        6
  Hu et al. \[[@B23]\]          2017   China     BC       RT-PCR   GAPDH         32/20                    OS                  Kaplan--Meier   50                 Indirectly        6
  Kobayashi et al. \[[@B20]\]   2016   Japan     CSCC     RT-PCR   GAPDH         24/25                    OS                  Multivariate    160                Indirectly        6
  Chen et al. \[[@B19]\]        2016   China     GC       RT-PCR   GAPDH         54/52                    OS                  Kaplan--Meier   120                Indirectly        8
  Song et al. \[[@B14]\]        2016   China     NPC      RT-PCR   GAPDH         76/32                    OS                  Kaplan--Meier   120                Indirectly        8

Abbreviations: BC, bladder cancer; CRC, colorectal cancer; CSCC, cervical squamous cell carcinoma;

ESCC, esophageal squamous cell carcinoma; GC, gastric cancer; NPC, nasopharyngeal carcinoma; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; RNU6B, RNA, U6 small nuclear 6B; OS, overall survival; PC, pancreatic cancer; PCa, prostate cancer.

###### Summary of the comparison for the *P*-values for the association between lncRNA XIST and clinicopathological characteristics

  Author                        Year   Country   Tumor type   Sample   Total number   Age     Gender   Tumor size   LNM      DM       Differentiation   Stage     Expression
  ----------------------------- ------ --------- ------------ -------- -------------- ------- -------- ------------ -------- -------- ----------------- --------- ------------
  Wu et al. \[[@B16]\]          2017   China     ESCC         Tissue   127            0.286   0.410    0.320        \-       \-       0.831             0.596     Up
  Wei et al. \[[@B21]\]         2017   China     PC           Tissue   64             0.798   0.317    0.006        0.131    0.079    \-                0.023     Up
  Du et al. \[[@B22]\]          2017   China     PCa          Tissue   62             0.324   \-       \-           \<0.01   \<0.01   \-                0.012     Down
  Hu et al. \[[@B23]\]          2017   China     BC           Tissue   52             0.540   0.658    0.028        0.042    \-       \-                0.012     Up
  Ma et al. \[[@B40]\]          2017   China     GC           Tissue   98             0.175   0.651    0.006        0.002    \-       \-                0.005     Up
  Mo et al. \[[@B37]\]          2017   China     HCC          Tissue   88             0.119   0.754    0.002        \-       \-       \-                \-        Up
  Du et al. \[[@B38]\]          2017   China     Glioma       Tissue   69             0.921   0.537    0.003        \-       \-       \-                \<0.001   Up
  Xiong et al. \[[@B39]\]       2017   China     BC           Tissue   67             0.389   \-       0.393        \-       0.901    0.418             0.036     Up
  Chen et al. \[[@B19]\]        2016   China     GC           Tissue   106            0.253   0.648    0.023        0.013    0.011    0.326             0.016     Up
  Fang et al. \[[@B15]\]        2016   China     NSCLC        Tissue   53             0.951   0.062    0.003        0.511    \-       0.0317            0.0002    Up
  Kobayashi et al. \[[@B20]\]   2016   Japan     CSCC         Tissue   49             0.12    \-       0.87         0.110    \-       \-                0.810     Down
  Tantai et al. \[[@B46]\]      2015   China     NSCLC        Tissue   32             0.549   0.717    0.010        0.001    \-       \-                \-        Up

Abbreviations: BC, bladder cancer; CSCC, cervical squamous cell carcinoma; DM, distant metastasis; ESCC, esophageal squamous cell carcinoma; GC, gastric cancer; HCC, hepatocellular carcinoma; LNM, lymph node metastasis; NSCLC, non-small-cell lung cancer; PC, pancreatic cancer; PCa, prostate cancer.

Association between XIST and prognosis {#sec3-2}
--------------------------------------

Because of absence of obvious heterogeneity amongst those 11 studies (*I^2^* \< 50%), the fixed-effect model was used to analyze the pooled HR and its 95% CI. The results showed that elevated XIST expression levels predicted poor prognosis (pooled HR = 1.81, 95% CI: 1.45--2.26) ([Figure 2](#F2){ref-type="fig"}). Afterward, the subgroups were divided by cancer types, sample sizes and, regions ([Figures 3](#F3){ref-type="fig"}--[5](#F5){ref-type="fig"}). According to the subgroup analysis, XIST could predict worse prognosis in digestive system tumors (pooled HR = 2.24, 95% CI: 1.73--2.92) than in non-digestive system tumors (pooled HR = 1.22, 95% CI: 0.60--2.45). Further, we did not observe significant heterogeneity in digestive system tumors (*I^2^* = 0.0%, *P*=0.990), indicating that the results in digestive system tumors were consistent and convincing. We also observed that the studies with sample sizes in excess of 100 were less heterogeneous than those studies whose sample sizes were less than 100, which suggested that increasing the sample size could be helpful to reduce the resources of heterogeneity. Regarding subgroup analysis on the basis of regions, we came to know that the studies from China (*I^2^*= 19.6%, *P*=0.269) were less heterogeneous than those from Ukraine and Japan (*I^2^* = 78.6%, *P*=0.031). The results were significant in China (pooled HR = 2.00, 95% CI: 1.57--2.56), whereas no significant result was observed in Ukraine and Japan (pooled HR = 0.66, 95% CI: 0.10--4.29). The results of subgroup analysis were summarized in [Table 3](#T3){ref-type="table"}.

![Forest plot for the relationship between XIST expression and overall survival](bsr-38-bsr20180169-g2){#F2}

![Subgroup analysis of overall survival by cancer types](bsr-38-bsr20180169-g3){#F3}

![Subgroup analysis of overall survival by sample sizes](bsr-38-bsr20180169-g4){#F4}

![Subgroup analysis of overall survival by regions](bsr-38-bsr20180169-g5){#F5}

###### Subgroup analysis of the pooled HRs with XIST expression in patients with cancer

  Subgroup analysis            Studies (*n*)   Number of patients   HR (95% CI)         Heterogeneity           
  ---------------------------- --------------- -------------------- ------------------- --------------- ------- ----------------
  **Cancer type**                                                                                               
  Digestive system tumor       6               580                  2.24 (1.73, 2.92)   0.0%            0.974   Random effects
  Non-digestive system tumor   5               340                  1.22 (0.60, 2.45)   71%             0.008   Random effects
  **Sample size**                                                                                               
  \>100                        4               552                  2.26 (1.66, 3.08)   0.0%            0.935   Random effects
  \<100                        7               368                  1.55 (1.02, 2.36)   58.2%           0.019   Random effects
  **Region**                                                                                                    
  China                        9               801                  2.00 (1.57, 2.56)   19.6%           0.269   Random effects
  Japan and Ukraine            2               119                  0.66 (0.10, 4.29)   78.6%           0.031   Random effects

Correlation of XIST and clinicopathological characteristics {#sec3-3}
-----------------------------------------------------------

Twelve studies were enrolled for clinicopathological characteristics consisting of 867 patients. Generally, age and gender had no effect on the expression levels of XIST (*P*\>0.05). Additionally, the levels of XIST generally varied with tumor size (*P*\<0.05). Studies with information of lymph node metastasis, distant metastasis, differentiation, and clinical stages were retrieved into OR analysis. We observed that high XIST expression was associated with positive distant metastasis (pooled OR = 2.28, 95% CI: 1.29--4.02) and clinical stages (pooled OR = 2.25, 95% CI: 1.67--3.03). There existed a significant heterogeneity for lymph node metastasis subgroup (*I^2^* = 75.3%, *P*=0.000) across studies included, therefore the random model was used to analyze the relationship between the expression levels of XIST and lymph node metastasis subgroup. And no significant results were observed (pooled OR = 1.86, 95% CI: 0.83--4.15). With respect to differentiation, we also observed no significance (pooled OR = 1.46, 95% CI: 0.92--2.33). The relationship between clinicopathological parameters and XIST expression levels was presented in [Table 4](#T4){ref-type="table"}. However, more studies were required to draw conclusive conclusions.

###### Pooled ORs for the relationship between XIST expression levels and clinicopathological parameters

  Category                                             Number of patients   OR (95% CI)         Heterogeneity           
  ---------------------------------------------------- -------------------- ------------------- --------------- ------- --------------
  Lymph node metastasis (yes compared with no)         516                  1.86 (0.83, 4.15)   75.3%           0.000   Random model
                                                                                                                        
  Distant metastasis (yes compared with no)            299                  2.28 (1.29, 4.02)   0.0%            0.532   Fixed model
                                                                                                                        
  Differentiation (poor compared with moderate/well)   353                  1.46 (0.92, 2.33)   16.8%           0.308   Fixed model
                                                                                                                        
  Tumor stage (III/IV compared with I/II)              747                  2.25 (1.67, 3.03)   61.7%           0.023   Random model
                                                                                                                        

Sensitivity analysis and publication bias {#sec3-4}
-----------------------------------------

The stability and reliability of the results were evaluated by sensitivity analysis. The results suggested that the conclusions were stable and reliable because the pooled HR was not significantly affected by any individual study ([Figure 6](#F6){ref-type="fig"}). And we evaluated the potential publication bias with Begg's test (*P*=0.024). *P*\<0.05 indicated that there existed publication bias ([Figure 7](#F7){ref-type="fig"}). Only English papers and positive studies might generate publication bias.

![Sensitivity of XIST expression for overall survival](bsr-38-bsr20180169-g6){#F6}

![Funnel plot of the publication bias for overall survival](bsr-38-bsr20180169-g7){#F7}

Reliability and conclusiveness of composite results {#sec3-5}
---------------------------------------------------

TSA was performed to estimate the sample size needed ([Figure 8](#F8){ref-type="fig"}). We assumed a 15% RRR with 80% power and two-sided α values of 0.05 to determine APIS for overall survival. The cumulative Z-curve (the blue one) crossed the traditional Z-curve (Z = 1.96), but failed to cross the TSA monitoring boundary (the red one), suggesting that the more trials were needed to confirm the positive result. For our meta-analysis, more well-designed studies with large sample sizes are necessary to improve the reliability and conclusiveness of composite results.

![TSA for overall survival based on APIS](bsr-38-bsr20180169-g8){#F8}

Discussion {#sec4}
==========

It is discovered that only 2% of the genomic sequences can code proteins, most of which are transcribed into non-coding RNA once considered to be the 'junk RNA' without biological function \[[@B25]\]. The development of high-throughput RNA sequencing technology provides an opportunity for us to discover non-coding RNA genes in great numbers \[[@B26]\]. Via interaction with DNA, RNA, or proteins, lncRNAs produce an effect on proliferation \[[@B27]\], potential invasion \[[@B28]\], resistance to radiation and drugs \[[@B29]\], and reprogrammed energy metabolism \[[@B30],[@B31]\]. Recently, accumulating evidence indicates that lncRNAs were closely associated with many diseases, such as cardiovascular diseases \[[@B32]\], autoimmune diseases \[[@B33]\], diabetes mellitus \[[@B34]\], and so on. Meanwhile, an increasing number of cancer-related lncRNAs are gradually characterized. Due to high sensitivity, specificity, and convenient detection in the body fluids, lncRNAs have great potential to be promising biomarkers for early detection and accurate prognosis for cancer patients \[[@B35]\].

The mechanism underlying the relationship between XIST and cancer outcome is uncertain. XIST is involved in X-chromosome inactivation in the cells of females and allows X-chromosome equilibration in males and females \[[@B36]\]. Loss of X-chromosome inactivation and abnormal expression of XIST are commonly observed in various cancers. The ceRNA regulatory network, in which XIST can compete for endogenous miRNAs was confirmed in nasopharyngeal carcinoma, esophageal squamous cell carcinoma, gastric cancer, pancreatic cancer, prostate cancer, hepatocellular carcinoma, glioma, bladder cancer \[[@B14],[@B19],[@B21],[@B37]\]. XIST could function as endogenous miRNA sponges to combine different miRNAs in different types of cancers, thus regulating proliferation, progression, and metastasis of tumors. In addition, Fang et al. \[[@B15]\] found that XIST could mediate its oncogenic effects through epigenetically silencing the expression of Kruppel-like factor (KLF2) via directly binding with enhancer of zeste homolog 2 (EZH2) in non-small-cell lung cancer. Furthermore, epithelial--mesenchymal transition (EMT) is a crucial step in tumor progression and metastasis \[[@B41]\]. XIST could mediate EMT by up-regulating epithelial markers (E-cadherin and β-catenin) and down-regulating mesenchymal markers in colorectal cancer \[[@B42]\]. XIST was involved in pathways related to tumorigenesis and cancer development, thus it had great therapeutic value and might contribute to personalized medicine therapy. One of the main strategies was using siRNAs to inhibit its expression. But the method is facing numerous challenges in clinical currently \[[@B43]\].

In order to combine the results of former studies about XIST and cancers, we elucidated the relationship between XIST expression levels and prognosis and also clinicopathological characteristics in cancer patients in the present meta-analysis. First, we performed to investigate the prognostic value of XIST in all kinds of tumors. The analysis showed the pooled HR was 1.81 (95% CI: 1.45--2.26), which suggested that elevated XIST expression levels were potentially related to poor prognosis. Then we observed higher predictive value of XIST in digestive system tumors (pooled HR = 2.24, 95% CI: 1.73--2.92) than in non-digestive system tumors (pooled HR = 1.22, 95% CI: 0.60--2.45) by subgroup analysis. Our meta-analysis showed elevated XIST expression levels in digestive system tumors predicted worse prognosis than in non-digestive system tumors for the first time. With regard to clinicopathological characteristics, our results indicated that elevated expression levels of XIST represented a greater possibility of distant metastasis (pooled OR = 2.28, 95% CI: 1.29--4.02) and high tumor stage (pooled OR = 2.25, 95% CI: 1.67--3.03). However, further large-scale studies should be conducted.

We cannot neglect that there exists some limitations in our analysis. First, more well-designed studies with large sample sizes need to be included in analysis. Second, some of the HRs were calculated by reconstructing survival curves rather than directly obtaining from the primary data. Third, most enrolled studies have positive results, but those with negative results were generally less likely to be published. In addition, patients included in this meta-analysis mostly came from People's Republic of China, which might diminish the overall effect of the results. Finally, our studies were only English papers, which might generate publication bias. Despite the limitations mentioned above, our meta-analysis is the first to reveal that lncRNA XIST has more predictive value in digestive system tumors, which suggest that lncRNA XIST can become a potential prognostic marker and predict cancer outcome in digestive system tumors. Well-designed studies related to specific cancer types with large sample sizes are required to confirm the prognostic value of lncRNA XIST in digestive system tumors. The cancer prevalence is inevitably increasing worldwide. Surveillance and monitoring systems should be strengthened to reverse the global trend. To fight against cancers, it must be a top priority to improve surveillance and monitoring levels \[[@B44]\]. Thus, the present study is clinically significant in exploring reliable biomarkers which can predict prognosis in malignant cancers.
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